Reversal of the anorectic effect of (+)‐fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK‐329
Open Access
- 1 January 1990
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 99 (1) , 65-70
- https://doi.org/10.1111/j.1476-5381.1990.tb14655.x
Abstract
1 Experiments were conducted to determine whether or not the effect of (+)-fenfluramine (3.0 mg kg−1, i.p.) on food intake can be antagonized by the selective cholecystokinin receptor antagonist MK-239 (formerly L364/718; (3S(−)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1-H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide). Two feeding paradigms were employed. In the first, non-deprived rats were familiarized with eating a highly palatable, sweetened mash in a 30 min test. In the second, freely-feeding rats were trained to consume powdered chow in their home-cages, and their intake was monitored over the first 6 h of the night-period. 2 In doses of 30.0 and 100.0 μg kg−1, s.c., MK-329 almost completely blocked the anorectic effect of (+)-fenfluramine in the palatable food intake test. These doses of MK-329 have previously been reported to antagonize the anorectic effect produced by exogenous cholecystokinin-octapeptide (CCK8) in rats. Both doses of MK-329 were also effective in significantly attenuating the anorectic effect of (+)-fenfluramine in nocturnal free-feeding animals over a 6 h-period. 3 MK-329 (10.0–100.0 μg kg−1, s.c.) failed to antagonize the anorectic effect of either the specific dopamine D2-receptor agonist quinpirole (0.3 mg kg−1, s.c.) or the β-carboline FG 7142 (10.0 mg kg−1, i.p.) in the palatable food intake test. 4 MK-329 (10.0–300.0 μg kg−1, s.c.) had no effect, when administered alone, on the level of palatable food intake in non-deprived rats, even when substantial satiation was produced by a pre-feeding procedure. Furthermore, MK-329 had no effect, when administered alone, on nocturnal food intake in freely-feeding rats. 5 In conclusion, not only was MK-329 a potent antagonist of the effect of CCK8 on food intake, it also blocked the effect of (+)-fenfluramine to a significant degree. The effect of MK-329 was selective in that the anorectic effects of either quinpirole or FG 7142 remained unaffected. Administered alone, MK-329 did not affect food intake, indicating that its reversal of (+)-fenfluramine-induced anorexia was not secondary to an intrinsic hyperphagic effect. The results provide some evidence that the depressant effect of (+)-fenfluramine on food intake depends on the activity of endogenous CCK.This publication has 33 references indexed in Scilit:
- C-Terminal octapeptide of cholecystokinin decreases food intake in obese menPublished by Elsevier ,2003
- Effects of dl-fenfluramine and xylamidine on gastric emptying of maintenance diet in freely feeding ratsEuropean Journal of Pharmacology, 1988
- Potency of L-364,718 as an antagonist of the behavioral effects of peripherally administered cholecystokininLife Sciences, 1988
- 5-HT1B agonists induce anorexia at a postsynaptic siteEuropean Journal of Pharmacology, 1987
- Proglumide fails to increase food intake after an ingested preloadPeptides, 1986
- Hyperphagic and anorectic effects of ß-carbolines in a palatable food consumption test: Comparisons with triazolam and quazepamEuropean Journal of Pharmacology, 1986
- Neurobiology of an anorectic drug: FenfluramineProgress in Neurobiology, 1986
- Effects of tifluadom on food consumption compared with chlordiazepoxide and kappa agonists in the ratNeuropharmacology, 1985
- The cholecystokinin antagonist, proglumide, increases food intake in the ratRegulatory Peptides, 1984
- Feeding behavior response of zucker rats to proglumide, a CCK receptor antagonist1Pharmacology Biochemistry and Behavior, 1983